UNICEF, the UN agency responsible for providing humanitarian and developmental aid to children worldwide, said on 23 February 2021 that it had sent an initial 100,000 syringes for COVID-19 vaccines to the Maldives in preparation for first deliveries of Pfizer and AstraZeneca shots under the COVAX vaccine-sharing plan, Reuters news agency reported on Tuesday.
According to the UNICEF, the syringes, as well as 1,000 safety boxes for vaccine storage, are expected to arrive in the Maldives on 23 February 2021.
Other recipient countries in the first wave of shipments include Ivory Coast and Sao Tome and Principe.
In a statement, the UNICEF said that the shipment of 23 February 2021 will be followed in the next few weeks by deliveries of about 14.5 million 0.5 millilitre (ml) and 0.3 ml syringes to over 30 countries.
The COVAX facility, co-led by the World Health Organisation, the GAVI vaccine alliance and others, had allocated about 330 million doses of COVID-19 vaccines for poorer countries earlier in February 2021. It aims to deliver these and millions more in the first half of 2021.
UNICEF said the 0.5 ml syringes would be for use with the AstraZeneca COVID-19 vaccine made by Serum Institute of India, while the 0.3 ml ones would be for the Pfizer-BioNTech shot.
UNICEF's executive director, Henrietta Fore, was quoted as saying: "It is critical to have adequate supplies of syringes already in place in every country before the vaccine arrives so that the vaccine can be administered safely," adding, "This would allow immunisation to start immediately and "help turn the tide on this terrible virus".
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Insilico Medicine signs multi-year research and development collaboration with Servier
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
MemorialCare hospitals recognised in 2026 Women's Choice Awards
International Isotopes Inc to change name to Radnostix Inc
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA